“Measuring protein biomarkers with Olink — technical comparisons and orthogonal validation” This white paper addresses how data from Olink studies compares to other technologies. We present examples of comparisons ranging from single-plex ELISAs to high multiplex assays and also provide useful tips for comparisons between Olink data and data from other technologies.
“Strategies for design of protein biomarker studies” This white paper describes important aspects of study design to consider when planning your future research. These include a well-defined study objective, adequate sample size, control of confounding factors and biases and appropriate statistical analysis. All procedures relevant to biomarker studies are covered, from initial planning, through sample collection and analysis to the final report. With the help of these guidelines, you can plan your studies to improve the chances of a successful outcome.
“Data normalization and standardization” This white paper describes how Olink data is processed and normalized to rapidly and reliably generate the easily understandable output from an Olink study. The topics covered include Olink’s built-in Quality Control system and a full description of how our Normalized Protein eXpression (NPX) values for relative quantification are calculated. The different normalization methods that can be used to optimize the output from often large and complex projects are also described in detail.
“Pre-analytical variation in protein biomarker research” This white paper considers some of the factors to consider when collecting, storing and handling human blood samples for use in protein biomarker studies. This article will discuss that while proteins are more sensitive than DNA in terms of potential pre-analytical factors, taking some basic precautions and documenting your sample-handling procedures should result in a successful outcome. The white paper draws on both the published literature and Olink’s experience in analyzing hundreds of thousands of samples over the past few years.
“Development and validation of customized PEA biomarker panels with clinical utility” This white paper describes the development of a customized 19-plex panel based on a new PEA protocol. With optimized molecular design and new conjugation chemistry, this enabled an assay in which high and low-abundant analytes could be combined into a single panel. In the proof-of-principle study described in the paper, calibrators were used for normalization and to enable absolute quantification of the measured proteins. Moreover, new validation processes are described which aim to ensure that panel is fit-for-purpose for future clinical utility.
“PEA: An enabling technology for high-multiplex protein biomarker discovery” This white paper describes the Proximity Extension Assay (PEA) technology that underlies Olink’s panels for protein biomarker discovery, development and implementation. This innovative technology is a method well suited for large-scale studies of protein biomarkers, offering good sensitivity, rapid, high-throughput analysis, and exceptional specificity at high-multiplex levels.